Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Worsening of disability caused by relapses in multiple sclerosis: A different approach.

Koch-Henriksen N, Thygesen LC, Sørensen PS, Magyari M.

Mult Scler Relat Disord. 2019 Jul;32:1-8. doi: 10.1016/j.msard.2019.04.017. Epub 2019 Apr 15.

PMID:
31003200
2.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
3.

Contribution of relapses to disability in multiple sclerosis.

Hirst C, Ingram G, Pearson O, Pickersgill T, Scolding N, Robertson N.

J Neurol. 2008 Feb;255(2):280-7. doi: 10.1007/s00415-008-0743-8. Epub 2008 Jan 23.

PMID:
18204919
4.

Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis.

Gasperi C, Salmen A, Antony G, Bayas A, Heesen C, Kümpfel T, Linker RA, Paul F, Stangel M, Tackenberg B, Bergh FT, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Tumani H, Gold R, Hemmer B; German Competence Network of Multiple Sclerosis.

JAMA Neurol. 2019 Jul 1;76(7):841-849. doi: 10.1001/jamaneurol.2019.0905.

PMID:
31034002
5.

Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.

Tilling K, Lawton M, Robertson N, Tremlett H, Zhu F, Harding K, Oger J, Ben-Shlomo Y.

Health Technol Assess. 2016 Oct;20(81):1-48.

6.
7.

[Influence of acute aggravations on the development of long-term handicap in relapsing remitting multiple sclerosis: a clinical study in 99 patients].

Gaillard N, Fabro-Perray P, Faillie JL, Le Bayon A, Castelnovo G, Dupeyron A, Froger J, Pelissier J, Labauge P.

Rev Neurol (Paris). 2007 Jan;163(1):72-81. French.

PMID:
17304175
8.

Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.

Prosperini L, Giannì C, Barletta V, Mancinelli C, Fubelli F, Borriello G, Pozzilli C.

J Neurol Sci. 2012 Dec 15;323(1-2):104-12. doi: 10.1016/j.jns.2012.08.027. Epub 2012 Sep 21.

PMID:
23006974
9.

Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis.

Young PJ, Lederer C, Eder K, Daumer M, Neiss A, Polman C, Kappos L; Sylvia Lawry Centre for Multiple Sclerosis Research.

Neurology. 2006 Sep 12;67(5):804-8.

PMID:
16966541
10.

Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.

Sormani MP, Li DK, Bruzzi P, Stubinski B, Cornelisse P, Rocak S, De Stefano N.

Neurology. 2011 Nov 1;77(18):1684-90. doi: 10.1212/WNL.0b013e31823648b9. Epub 2011 Oct 5.

PMID:
21975200
11.

Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis.

Ahrweiller K, Rousseau C, Le Page E, Bajeux E, Leray E, Michel L, Edan G, Kerbrat A.

Mult Scler. 2019 May 16:1352458519848090. doi: 10.1177/1352458519848090. [Epub ahead of print]

PMID:
31094285
12.

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.

Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M.

Neurology. 2001 Oct 9;57(7):1239-47.

PMID:
11591843
13.

Mitoxantrone in worsening secondary progressive multiple sclerosis: A prospective, open-label study.

Khatri BO, Wroblewski M, Kramer J, Dukic M, Poplar A, Anderson AJ.

Curr Ther Res Clin Exp. 2006 Jan;67(1):55-65. doi: 10.1016/j.curtheres.2006.02.004.

15.

Management of worsening multiple sclerosis with mitoxantrone: a review.

Fox EJ.

Clin Ther. 2006 Apr;28(4):461-74. Review.

PMID:
16750460
16.

Impact of multiple sclerosis relapses on progression diminishes with time.

Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y; UBC Neurologists.

Neurology. 2009 Nov 17;73(20):1616-23. doi: 10.1212/WNL.0b013e3181c1e44f. Epub 2009 Nov 4.

17.
18.

Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada.

Karampampa K, Gustavsson A, Miltenburger C, Kindundu CM, Selchen DH.

J Popul Ther Clin Pharmacol. 2012;19(1):e11-25. Epub 2012 Jan 10.

PMID:
22247419
19.

Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy.

Chalmer TA, Kalincik T, Laursen B, Sorensen PS, Magyari M; Members of Danish Multiple Sclerosis Group.

J Neurol. 2019 Feb;266(2):306-315. doi: 10.1007/s00415-018-9126-y. Epub 2018 Dec 4.

PMID:
30515628
20.

The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.

Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, Ebers GC.

Brain. 2010 Jul;133(Pt 7):1914-29. doi: 10.1093/brain/awq118. Epub 2010 Jun 9.

Supplemental Content

Support Center